Mezabiome Therapies Limited
Biotechnology Research • 
Sydney, New South Wales, Australia • 1-10 Employees
Company overview
| Headquarters | Sydney, New South Wales, Australia |
| Website | |
| NAICS | 541714 |
| Keywords | Microbiome, Clinical Efficiency, Biotechnolgy, Patient Outcomes, FMT, Fecal Microbiota Transplant |
| Founded | 2024 |
| Employees | 1-10 |
Key Contact at Mezabiome Therapies Limited
Jason Borody
Non-Executive Director
About Mezabiome Therapies Limited
Mezabiome is advancing the efficacy and efficiency of fecal microbiota transplants (FMT) through a proprietary suite of hardware and consumables. We employ a unique process to dissolve gastrointestinal biofilms, verify biofilm removal in real-time and deliver microbiota directly to the engraftment site once the biofilm is cleared. Our holistic approach represents a meaningful advancement in microbiome therapies, aligning treatment timing with the body’s readiness for microbiota restoration. This targeted strategy not only enhances microbiota transplantation, reduces disease recurrence, and improves patient outcomes but also benefits clinicians by streamlining the FMT process, providing precision tools for improved control, and reducing procedure time and complexity.
Mezabiome Therapies Limited revenue & valuation
| Annual revenue | $256,665 |
| Revenue per employee | $86,000 |
| Estimated valuation?This valuation is estimated based on industry average for the Biotechnology Research industry and current estimated revenues | $821,328 |
| Total funding | No funding |
Employees by Management Level
Total employees: 1-10
Seniority
Employees
Funding Data
Mezabiome Therapies Limited has never raised funding before.
United States
Algeria
Czechia
United KingdomFrequently asked questions
4.8
40,000 users
